Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.1059
Abstract: Importance Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear. Objective To determine whether adding denosumab to… read more here.
Keywords: denosumab; trial; nab paclitaxel; randomized clinical ... See more keywords
Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4715
Abstract: This trial was conducted to compare the efficacy of low dose once‐a‐week cisplatin and once‐every‐3‐weeks cisplatin with radiation in locally advanced head and neck squamous cell carcinoma (LAHNSCC). The current analysis focuses on the quality… read more here.
Keywords: locally advanced; head neck; advanced head; weeks cisplatin ... See more keywords
Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1113
Abstract: Tralokinumab is the first biologic therapy for moderate‐to‐severe atopic dermatitis (AD) that specifically neutralizes interleukin‐13 activity, a key driver of AD signs and symptoms. Tralokinumab is a human immunoglobulin G4 monoclonal antibody administered subcutaneously every… read more here.
Keywords: severe atopic; moderate severe; atopic dermatitis; exposure ... See more keywords
Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.936
Abstract: Intravenous (IV) atezolizumab is approved for non–small cell lung and other cancers. Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase, a permeation enhancer for SC dispersion and absorption, is being developed to improve treatment options,… read more here.
Keywords: phase; cell lung; atezolizumab; every weeks ... See more keywords
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1855
Abstract: PERJETA (pertuzumab), administered with Herceptin (trastuzumab), is used in the treatment of human epidermal growth factor receptor 2‐positive breast cancer. Pertuzumab is currently approved with an initial loading dose of 840 mg, followed by a… read more here.
Keywords: impact dose; pertuzumab; dosing regimens; alternative dosing ... See more keywords
Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2055
Abstract: We characterized the population pharmacokinetics of anifrolumab, a type I interferon receptor–blocking antibody. Pharmacokinetic data were analyzed from the anifrolumab (intravenous [IV], every 4 weeks) arms from 5 clinical trials in patients with systemic lupus… read more here.
Keywords: pharmacokinetics anifrolumab; healthy volunteers; patients systemic; population pharmacokinetics ... See more keywords
Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab
Sign Up to like & getrecommendations! Published in 2021 at "Digestive Diseases and Sciences"
DOI: 10.1007/s10620-021-06852-3
Abstract: A 27-year-old female with a history of hypertension was diagnosed with pan-ulcerative colitis (UC) after experiencing several weeks of diarrhea, hematochezia, and abdominal cramping. She was initially treated with 5-ASA and azathioprine, both of which… read more here.
Keywords: vedolizumab; infliximab; colitis; ulcerative colitis ... See more keywords
Efficacy, Tolerability, and Biomarker Analyses of Once‐Every‐2‐Weeks Cetuximab Plus First‐Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild‐Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Colorectal Cancer"
DOI: 10.1016/j.clcc.2016.08.005
Abstract: Micro‐Abstract The nonrandomized phase 2 APEC trial investigated first‐line once‐every‐2‐weeks cetuximab plus chemotherapy (investigator's choice of FOLFOX or FOLFIRI) studied patients with KRAS/RAS wild‐type metastatic colorectal cancer. We observed an activity and safety profile similar… read more here.
Keywords: folfox folfiri; weeks cetuximab; line; first line ... See more keywords
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.09.009
Abstract: PURPOSE DTS-201 is a doxorubicin (Dox) prodrug that shows encouraging data in experimental models in terms of both efficacy and safety compared with conventional Dox. The purpose of this phase I study was to assess… read more here.
Keywords: phase; safety; dts 201; every weeks ... See more keywords
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three‐year results from the UNCOVER‐3 study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2018.05.032
Abstract: Background Psoriasis is a chronic disease that may require long‐term treatment. Ixekizumab (IXE), which is a high‐affinity monoclonal antibody that selectively targets interleukin 17A, is an approved therapy for patients with moderate‐to‐severe plaque psoriasis. Objective… read more here.
Keywords: uncover study; pasi score; treatment; improvement baseline ... See more keywords
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study.
Sign Up to like & getrecommendations! Published in 2020 at "Ophthalmology"
DOI: 10.1016/j.ophtha.2020.03.035
Abstract: PURPOSE To compare the efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) versus ranibizumab every 4 weeks in treatment-naïve patients with neovascular age-related macular degeneration (AMD). DESIGN Two randomized, multicenter,… read more here.
Keywords: week; treatment; safety; study ... See more keywords